Aion Medicines

Aion Medicines is a private, preclinical-stage biotech tackling the chronic disease epidemic through an ultra-long-acting drug delivery platform. Its primary asset, AM-710, is a small-molecule GLP-1R agonist in development for type 2 diabetes and obesity with potential dosing intervals of three to six months or longer, aiming for a best-in-class profile. The company is led by a team with deep drug development experience and is supported by a high-profile scientific advisory board. Aion operates in a pre-revenue stage, targeting massive markets with significant unmet needs in patient adherence.

Platform for developing ultra-long-acting therapeutics with extended pharmacokinetic profiles, aiming for multi-month dosing intervals through formulation and medicinal chemistry.

Aion competes directly with major pharmaceutical companies (e.g., Novo Nordisk, Eli Lilly) advancing next-generation GLP-1 therapies, including oral and longer-acting injectable formulations. In opioid use disorder, it would compete with existing MAT therapies like buprenorphine implants and injections. Its key differentiator is the pursuit of potentially the longest dosing intervals.